PATENT CLAIM ANALYSIS

Application Number: 15885671
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["514", "220000"]

Abstract:
The description relates to cereblon E3 ligase binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.

Claim (Index 7):
The bifunctional compound of  claim 2 , wherein the CLM is represented by a chemical structure selected from the group consisting of: wherein Rn comprises a functional group or an atom.

Metadata:
- Claim Count in Document: 19.0
- Percentile: 86.0
- Lexical Diversity: 1.675
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15881318', '15730728', '14822309', '16346483', '15148253']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8111758496821463
- 35 USC 102 Novelty (BERT): 0.5659786252736122
- Combined Prediction Score: 0.7866561272412929
- Mean Citation Score: 336.657926
- Max Citation Score: 477.86942
- Similarity Product: 310.0018390302527

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test